Paracetamol


Concise Prescribing Info
Indications/Uses
Mild to moderate pain and fever.
Dosage/Direction for Use
Adult: PO 0.5-1 g 4-6 hourly. IV 33-50 kg: 15 mg/kg 4-6 hourly if needed. Max: 3 g/day: >50 kg: 1 g 4-6 hourly if needed. Rectal As supp: 0.5-1 g 4-6 hourly. Max: 4 g daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Severe hepatic impairment or active liver disease (IV).
Special Precautions
Patient with known G6PD deficiency, alcohol dependence, chronic malnutrition or dehydration, weight <50 kg; severe hypovolaemia (IV). Renal and hepatic impairment. Children. Pregnancy and lactation. Monitoring Parameters Assess patient for history of liver disease or alcohol abuse.
Adverse Reactions
Significant: Thrombocytopenia, leucopenia, neutropenia, pancytopenia, methaemoglobinaemia, agranulocytosis, angioedema, pain and burning sensation at inj site. Rarely, hypotension and tachycardia. Gastrointestinal disorders: Nausea, vomiting, constipation. Nervous system disorders: Headache. Psychiatric disorders: Insomnia. Skin and subcutaneous tissue disorders: Erythema, flushing, pruritus.
Potentially Fatal: Hepatotoxicity, acute renal tubular necrosis. Rarely, hypersensitivity reactions such as acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN).
ROUTE(S) : PO: B
ROUTE(S) : Parenteral / IV: C
Drug Interactions
Decreased absorption with cholestyramin. Decreased serum concentrations with rifampicin and some anticonvulsants (e.g. phenytoin, phenobarbital, carbamazepine, primidone). Enhances the anticoagulant effect of warfarin and other coumarins with prolonged use. Increased absorption with metoclopramide and domperidone. Increased serum concentration with probenecid. May increase serum concentration of chloramphenicol.
ATC Classification
N02BE01 - paracetamol ; Belongs to the class of anilide preparations. Used to relieve pain and fever.
Disclaimer: This information is independently developed by CIMS based on paracetamol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in